Pnd26 - Cost Implications of a Novel Weight Dosed Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1993
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pnd27 - Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Advances in Therapy
MedicinePharmacology
2019English

Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber
Pharmacology
2018English

Pnd29 - Long Range Simulation of the Cost Burden of Difference Treatment Sequences Approved for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy